“Amid high-priority efforts to eliminate hepatitis as a major public health threat, diagnostics must play a crucial role. With the boon of additional molecular testing capacity built during the pandemic, many clinical laboratories now have the chance to scale up their hepatitis screening to contribute to these efforts – a rare and hard-won opportunity that could have significant benefits for global health.”

- Erica Frew is Product Manager at Asuragen, a Bio-Techne brand, where she specializes in molecular controls for clinical tests.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

I have read and understand the Privacy Notice*

Subscribe